Abstract: The present invention relates to a method for obtaining monoclonal human antibodies directed against an infectious pathogen, monoclonal human antibodies or binding fragments thereof which are directed against an infectious pathogen as obtained by the method of the invention, a pharmaceutical composition comprising such monoclonal human antibodies, a kit comprising such antibodies, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament and in the treatment or prevention of a disease caused by the infectious pathogen.

Abstract: The present disclosure relates generally to modified NK cell compositions and methods of using the modified cell compositions in immunotherapy applications. In embodiments, the modified cell express a ? chain and a ? chain. In embodiments, the modified NK cell compositions can be used to treat various cancers.

Abstract: Among the various aspects of the present disclosure is the provision of improved chimeric receptor constructs for NK cells, NK cells containing such receptors and methods of making and using same.

Abstract: Chimeric antigen receptors containing fully human CD20/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Abstract: A CD7-targeted engineered immune cell, a chimeric antigen receptor, a CD7 blocking molecule and the use thereof. A natural ligand of human CD7 is used for substituting for an antibody sequence to serve as an antigen recognition domain of a CD7-specific CAR-T or CAR-NK cell. The advantage of using human CD7 as the antigen recognition domain in the CD7-specific CAR is that cellular and humoral reactions produced by a host can be prevented, to achieve long-term durability and better efficacy of the CAR-T cell.

Abstract: This disclosure relates to therapeutics containing IL-37, chimeric antigen receptors, nucleic acids, or vectors encoding the same. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 to a subject diagnosed with cancer and administering T cells expressing a chimeric antigen receptor to the subject. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 and a chimeric antigen receptor to a subject diagnosed with cancer.

Abstract: Disclosed herein are electrotransfer (ET) methods for delivering therapeutic agents to tumors. Also disclosed are methods of using the ET methods for differential delivery of an agent to more than one tissue. For example, the ET methods can be used to deliver soluble peptides of PD1 to tumor tissue to block normal PD1-PDL1 binding while separately using the ET methods to deliver PD1 or PDL1 antigen to another tissue, such as skin or muscle, to induce systemic and polyclonal checkpoint inhibitor antibodies.

Abstract: The present disclosure provides an integrated target assembly containing a lithium layer attached to a base plate on a support structure made from a low-activation material. The support structure includes flow channels adjacent to the surface of the base plate for effective cooling of the base plate during operation. The integrated target assembly advantageously reduces the amount of easily activatable material, such as copper, leading to increased safety of the handling personnel.

Abstract: The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

Abstract: A poly-ion complex micelle comprising: a block copolymer having a hydrophilic block portion, a cationic hydrophobic block portion and a crosslinking block portion positioned between the hydrophilic block and the cationic hydrophobic block, and an anionic molecule drug encapsulated by the block copolymer, wherein the crosslinking block has a hydrazone bond, the block copolymer comprises the first block copolymer chain and the second block copolymer chain, the first block copolymer chain and the second block copolymer chain crosslinked to each other in the crosslinking block portion, the hydrophilic block portion comprises the first hydrophilic block of the first block copolymer chain and the second hydrophilic block of the second block copolymer chain, and the cationic hydrophobic block portion comprises the first cationic hydrophobic block of the first block copolymer chain.

Abstract: This disclosure provides multifunctional conjugate molecules comprising a target binding component covalently linked to one or more cannabinoids and/or one or more cannabinoid conjugate components. In some embodiments, the target binding component also is covalently linked to one or more active agent components. The disclosed conjugate molecules are designed to deliver therapeutic benefits of each component of the conjugate molecules and can be used to treat cancer and other disorders.

Abstract: The present invention relates to conjugates comprising reversible linkers and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said conjugates and the use of said conjugates as medicaments.

Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

Abstract: Supramolecular assemblies, compositions thereof, and methods for preparing and use the same are provided. The supramolecular assemblies comprise a trimeric variant of a GCN4 peptide capable of self-assembly and incorporating one or more guest molecules in a functional 3D native structure.

Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Abstract: An isolated IgG antibody includes two identical heavy chains each having a hinge region with an amino acid sequence containing an additional cysteine upstream of the two cysteines in the CPPCP sequence of a native IgG hinge region, and a CH1 domain containing a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs based on the antibody having this architecture are also provided.

Abstract: The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.

Abstract: The present disclosure provides compositions for targeting neutrophil extracellular traps for diagnostic and therapeutic purposes (e.g., for treating inflammation in conditions or diseases associated with accumulation of neutrophil extracellular traps in a subject in need thereof).

Abstract: Disclosed are antibodies and antibody drug conjugates having an Fc region with substitutions resulting in essentially a silent Fc region. The antibodies and antibody drug conjugates described herein are useful for the depletion of cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting, e.g., a population of CD45+ or CD117+ cancer cells or CD45+ autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

Abstract: Provided are a complex of an anti-IL-4R antibody or an antigen-binding fragment thereof, and a medical use thereof. Specifically, provided are a complex of an antibody that specifically binds to IL-4R or an antigen-binding fragment thereof covalently linked to a toxin, a pharmaceutical composition comprising the complex, and a use thereof in the preparation of a drug for treating IL-4R-mediated diseases or disorders, especially a use in the preparation of an anti-cancer drug.

Abstract: A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: Provided herein are methods of treating cancer in a human subject, comprising administering to the subject: i) an antibody-drug conjugate (ADC) comprising an antibody, a cleavable linker and a cytotoxic agent, and ii) a bispecific checkpoint inhibitor. Further provided herein are kits comprising i) an antibody-drug conjugate (ADC) comprising an antibody, a cleavable linker and a cytotoxic agent, and ii) a bispecific checkpoint inhibitor.

Abstract: An engineered targeting exosome comprising; a modified Lamp2b peptide, a targeting peptide or antibody; and a Fc portion of IgG2b. The targeting peptide or antibody detects a target protein within a cell and precisely delivers the exosome to cells expressing the target protein and the Fc portion of IgGb2 induces antibody-dependent cell-mediated cytotoxicity (ADCC) events in cells expressing the target protein. Also disclosed are methods of using the engineered targeting exosome to detect and/or deplete cells expressing the target protein.

Abstract: The present invention is related to reduced graphene oxide (rGO) nanoplatforms coated with a methacrylate-based copolymer and the methods used in the preparation of these platforms for use as a drug carrier system.

Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Abstract: A method for in utero genome editing, the method comprising administering to a subject an adenoviral vector, wherein the subject is a fetus, the adenoviral vector comprising CRISPR-mediated base editor and a guide RNA (gRNA), the gRNA targeting a mutation in a therapeutic gene; and introducing a modified codon in the therapeutic gene by base editing the therapeutic gene, wherein the base editing is performed by the adenoviral vector, an adeno-associated viral vector or lipid based nanoparticle.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Abstract: The disclosure provides methods and compositions that employ gene editing for the treatment of cancer. Gene editing systems specifically target tumor DNA to introduce an expression cassette with a coding sequence that is expressed by tumor cells as a neoantigen that mark the tumor cells for cell death.

Abstract: The present invention relates to a method for selectively transducing retinal and optic nerve head (ONH) astrocytes using adeno-associated virus serotype 5 (AAV5) in combination with a modified glial fibrillary acidic protein promoter (gfaABC1D) for delivery of gene therapies (recombinant DNA, shRNA, Crispr/Cas9) to treat glaucoma or other optic neuropathies

Abstract: Disclosed herein are methods for regulating an immune response using selective activation of neurons in the caudal nucleus of the solitary tract.

Abstract: The present disclosure relates to methods of inducing central nervous system (CNS) injuries in an animal model for use of identifying and/or screening CNS therapeutic compositions.

Abstract: The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

Abstract: Disclosed are a gallium 68 labeled affibody protein PET imaging agent and a use thereof; the imaging agent comprises 68Ga-Z-tri; the 68Ga-Z-tri is obtained by labeling an affibody protein with gallium 68; the affibody protein comprises a PDGFR-? targeting trimer affibody protein Z-tri; and the amino acid sequence listing of the affibody protein Z-tri is as shown in SEQ ID NO. 1. According to the present invention, the utilized PDGFR-? targeting trimer affibody having a unique amino acid sequence has the characteristics of high affinity and high stability compared with a monomer affibody and a dimer affibody, can greatly increase a nuclide labeling rate, and achieves the effectiveness thereof as a PET imaging probe.

Abstract: The present application provides a merchandiser with a number of packages therein. The merchandiser may include a product area with either a number of shelves or a number of columns with the packages therein and a package sanitation system. The package sanitation system may include one or more ultraviolet lights positioned within the product area so as to sanitize the packages therein.

Abstract: A method of decontaminating a surface includes exposing the surface to germicidal UV light emitted by at least one germicidal UV light source, preferably a light emitting diode (LED), for a continuous exposure period of between 0.05 seconds and 2 seconds; discontinuing the exposure of the surface to the germicidal UV light for a continuous rest period of between 30 seconds and 120 seconds; and repeating steps a. and b. for a total of at least 3 cycles.

Abstract: A baggage disinfection system forming a tunnel is provided. The system has a roller assembly operated by a motor that causes the roller assembly to convey objects at a rate of between about 0.10 m/second and about 0.50 m/second from an entry end of the system to an exit end of the system, such that the travel time between the entry end of the system and the exit end of the system is less than or equal to about 30 seconds. In one embodiment, the system is capable of inactivating at least 99.9% of Sars-Cov-2 viruses passing through the tunnel within the travel time. In other embodiments, the travel time is less than about 10 seconds, and the system is capable of inactivating at least 99.9% of Sars-Cov-2 or mutations thereof passing through the tunnel, or 99.99% of Sars-Cov-2 or mutations thereof passing through the tunnel.

Abstract: An apparatus and method for sterilization of an article which has a first open end, a second open end and a lumen extending therebetween. The apparatus comprises a first chamber for receiving the article. The first chamber has an outlet fluidly connectable to a pump for adjusting an internal pressure in the first chamber; and an inlet fluidly connectable to a sterilant source for supplying sterilant to the first chamber. The apparatus includes a second chamber fluidly connectable to the first chamber by a chamber connector fluidly sealable to isolate the first and the second chamber; and an article connector for fluidly connecting the second open end of the article to the second chamber to form a fluid path from the first to the second chamber through the lumen. Also included is an article connector for connecting an open end of an article to be sterilized to a sterilization apparatus.

Abstract: In the COP treatment and the SOP treatment of the interior of a chamber of an aseptic filler, any cleaning liquid or aseptic water remaining in the chamber is quickly removed before spray of a sterilizer containing peracetic acid or hydrogen peroxide. A transfer device for transferring a container in the chamber of the aseptic filler is driven to remove the cleaning liquid sued for the COP treatment or the aseptic water used for the SOP treatment.

Abstract: A scent dispenser may comprise a vial retaining mechanism, a heating element, vial sensor, and a controller. The vial retaining mechanism includes a vial coupling that removeably retains a vial containing a scented solution. The includes a wick extending from a cavity of the vial through an opening of a neck of the vial. The heating element is shaped to receive and heat the wick of the vial. The vial sensor includes an array of sensor pads that are arranged in alignment with the vial retained by the vial coupling. The controller is electrically coupled to the heating element and electrically coupled to the array of sensor pads. The controller regulates a temperature level of the heating element, and receives signals from the array of sensor pads and processing the signals to determine a fluid level of the vial.

Abstract: The invention relates to a pharmaceutical unit (12) and to a method for operating a pharmaceutical unit (12).

Abstract: A plasma generation module includes a first electrode that includes a linear structure of a flexible material; a second electrode having a structure made of a flexible material and is disposed opposite to the first electrode. The first electrode and the second electrode are configured to form a linear discharge region between the first electrode and the second electrode. The plasma generation module includes a dielectric layer provided between the first electrode and the second electrode.

Abstract: Disclosed is an odor removal device. The odor removal device includes: a case; an activation device installed in the case and coming into contact with an object to activate surrounding materials according to a dielectric barrier discharge principle, wherein the activation device includes: a dielectric having an outer surface exposed to an outside and provided as a curved surface; and an electrode positioned inside the dielectric in which power is applied to the electrode.

Abstract: The disclosure provides monolithic-style dermal patches and reservoir-style dermal patches, where the dermal patch is capable of delivering a mixture of anti-pain drugs to the skin. Provided also are methods for manufacturing said dermal patches.

Abstract: Decellularized matrix microspheres comprising a polymeric material and a donor tissue are provided. Also disclosed are structures containing a plurality of decellularized matrix microspheres incorporating a first polymer and a donor tissue; and a second polymer, wherein the decellularized matrix microspheres and the second polymer are in the form of a filament. Methods of treating a tissue injury employing the matrix microspheres and structures described as well as their methods of manufacture are also provided.

Abstract: Provided are biodegradable orthopedic implants, corrosion-resistant coating for orthopedic implants, and methods of making. The biodegradable orthopedic implant can include a Mg alloy having a coating including a first layer, a second layer, and a third layer. The first layer can be an oxide layer coated on an external surface of a magnesium alloy implant. The second layer can include lawsone embedded in PCL, and the third layer can include PCL. To manufacture the coated orthopedic implant, the implant can be immersed in an alkaline solution to form an oxide-coated implant and implant can then be coated with a PCL lawsone solution. An additional polymer protective layer can be added.

Abstract: Provided are compositions and methods of making a hydrogel-forming composition comprising decellularized porcine nucleus pulposus tissue that is solubilized and supplemented with collagen, then neutralized and thermally gelled in the presence of genipin. The hydrogel-forming composition may be injected into a joint or surrounding tissue of a subject having pain or inflammation. The pain or inflammation may be caused by degeneration of the intervertebral disc (IVD), wherein administration of the hydrogel-forming composition into the IVD may restore the lost disc volume and alleviate the pain and inflammation.

Abstract: A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation.

Abstract: The present invention discloses a dry biological tissue material and a method of preparing the material.

Abstract: A method for forming a bioactive agent spatially patterned includes providing a photocrosslinkable hydrogel that includes a photocrosslinkable base polymer, photocrosslinkable bioactive agent coupling polymer macromers, and at least one bioactive agent that couples to the photocrosslinkable bioactive agent coupling polymer macromer, an selectively exposing discrete portions of the photocrosslinkable hydrogel to actinic radiation effective to initiate cross-linking of the base polymer and the bioactive agent coupling polymer macromers at the exposed portions.